Denny Lanfear, Coherus BioSciences CEO
January 10, 2023 04:24 PM ESTUpdated January 12, 10:51 AM
Deals

Co­herus pays out $32M for ex­clu­sive US com­mer­cial­iza­tion rights to Eylea biosim­i­lar

Paul Schloesser

Associate Editor

Co­herus Bio­Sciences is adding to its pipeline, this time grab­bing com­mer­cial­iza­tion rights for a biosim­i­lar of one of the largest oph­thal­mol­o­gy drugs on the mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times